216 related articles for article (PubMed ID: 36725433)
1. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP).
Raabe V; Lai L; Morales J; Xu Y; Rouphael N; Davey RT; Mulligan MJ
Vaccine; 2023 Feb; 41(8):1513-1523. PubMed ID: 36725433
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Huttner A; Agnandji ST; Engler O; Hooper JW; Kwilas S; Ricks K; Clements TL; Jonsdottir HR; Nakka SS; Rothenberger S; Kremsner P; Züst R; Medaglini D; Ottenhoff T; Harandi AM; Siegrist CA; ; ;
Clin Microbiol Infect; 2023 Dec; 29(12):1587-1594. PubMed ID: 37661067
[TBL] [Abstract][Full Text] [Related]
3. Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
Grais RF; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BA; Welebob C; Hanson ME; Simon JK
Lancet Microbe; 2021 Feb; 2(2):e70-e78. PubMed ID: 35544244
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
Simon JK; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BG; Welebob C; Hanson ME; Grais RF
Vaccine; 2022 Nov; 40(46):6599-6606. PubMed ID: 36208978
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Lee AW; Liu K; Lhomme E; Blie J; McCullough J; Onorato MT; Connor L; Simon JK; Dubey S; VanRheenen S; Deutsch J; Owens A; Morgan A; Welebob C; Hyatt D; Nair S; Hamzé B; Guindo O; Sow SO; Beavogui AH; Leigh B; Samai M; Akoo P; Serry-Bangura A; Fleck S; Secka F; Lowe B; Watson-Jones D; Roy C; Hensley LE; Kieh M; Coller BG;
Clin Infect Dis; 2024 Apr; 78(4):870-879. PubMed ID: 37967326
[TBL] [Abstract][Full Text] [Related]
6. Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis.
Antonello J; Grant-Klein RJ; Nichols R; Kennedy SB; Dubey S; Simon JK
Vaccine; 2020 Jun; 38(31):4885-4891. PubMed ID: 32499064
[TBL] [Abstract][Full Text] [Related]
7. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
[TBL] [Abstract][Full Text] [Related]
8. Characterization of rVSVΔG-ZEBOV-GP glycoproteins using automated capillary western blotting.
Minsker K; Rustandi RR; Ha S; Loughney JW
Vaccine; 2020 Oct; 38(45):7166-7174. PubMed ID: 32951937
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.
Vianello E; Gonzalez-Dias P; van Veen S; Engele CG; Quinten E; Monath TP; Medaglini D; ; ; Santoro F; Huttner A; Dubey S; Eichberg M; Ndungu FM; Kremsner PG; Essone PN; Agnandji ST; Siegrist CA; Nakaya HI; Ottenhoff THM; Haks MC
Lancet Microbe; 2022 Feb; 3(2):e113-e123. PubMed ID: 35544042
[TBL] [Abstract][Full Text] [Related]
10. Correlates of vaccine-induced protective immunity against Ebola virus disease.
Medaglini D; Santoro F; Siegrist CA
Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.
Dahlke C; Kasonta R; Lunemann S; Krähling V; Zinser ME; Biedenkopf N; Fehling SK; Ly ML; Rechtien A; Stubbe HC; Olearo F; Borregaard S; Jambrecina A; Stahl F; Strecker T; Eickmann M; Lütgehetmann M; Spohn M; Schmiedel S; Lohse AW; Becker S; Addo MM;
EBioMedicine; 2017 May; 19():107-118. PubMed ID: 28434944
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
Boum Y; Juan-Giner A; Hitchings M; Soumah A; Strecker T; Sadjo M; Cuthbertson H; Hayes P; Tchaton M; Jemmy JP; Clarck C; King D; Faga EM; Becker S; Halis B; Gunnstein N; Carroll M; Røttingen JA; Kondé MK; Doumbia M; Henao-Restrepo AM; Kieny MP; Cisse M; Draguez B; Grais RF
Vaccine; 2020 Jun; 38(31):4877-4884. PubMed ID: 32499066
[TBL] [Abstract][Full Text] [Related]
13. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.
Monath TP; Fast PE; Modjarrad K; Clarke DK; Martin BK; Fusco J; Nichols R; Heppner DG; Simon JK; Dubey S; Troth SP; Wolf J; Singh V; Coller BA; Robertson JS;
Vaccine X; 2019 Apr; 1():100009. PubMed ID: 31384731
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.
Hoff NA; Bratcher A; Kelly JD; Musene K; Kompany JP; Kabamba M; Mbala-Kingebeni P; Dighero-Kemp B; Kocher G; Elliott E; Reilly C; Halbrook M; Ilunga Kebela B; Gadoth A; Ngoie Mwamba G; Tambu M; McIlwain DR; Mukadi P; Hensley LE; Ahuka-Mundeke S; Rutherford GW; Muyembe-Tamfum JJ; Rimoin AW
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35110410
[TBL] [Abstract][Full Text] [Related]
15. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
Halperin SA; Arribas JR; Rupp R; Andrews CP; Chu L; Das R; Simon JK; Onorato MT; Liu K; Martin J; Helmond FA;
J Infect Dis; 2017 Jun; 215(12):1789-1798. PubMed ID: 28549145
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.
Halperin SA; Das R; Onorato MT; Liu K; Martin J; Grant-Klein RJ; Nichols R; Coller BA; Helmond FA; Simon JK;
J Infect Dis; 2019 Aug; 220(7):1127-1135. PubMed ID: 31505665
[TBL] [Abstract][Full Text] [Related]
17. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG
PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239
[TBL] [Abstract][Full Text] [Related]
19. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
Ewer K; Rampling T; Venkatraman N; Bowyer G; Wright D; Lambe T; Imoukhuede EB; Payne R; Fehling SK; Strecker T; Biedenkopf N; Krähling V; Tully CM; Edwards NJ; Bentley EM; Samuel D; Labbé G; Jin J; Gibani M; Minhinnick A; Wilkie M; Poulton I; Lella N; Roberts R; Hartnell F; Bliss C; Sierra-Davidson K; Powlson J; Berrie E; Tedder R; Roman F; De Ryck I; Nicosia A; Sullivan NJ; Stanley DA; Mbaya OT; Ledgerwood JE; Schwartz RM; Siani L; Colloca S; Folgori A; Di Marco S; Cortese R; Wright E; Becker S; Graham BS; Koup RA; Levine MM; Volkmann A; Chaplin P; Pollard AJ; Draper SJ; Ballou WR; Lawrie A; Gilbert SC; Hill AV
N Engl J Med; 2016 Apr; 374(17):1635-46. PubMed ID: 25629663
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
